These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28235250)

  • 1. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone.
    Tamirou F; Husson SN; Gruson D; Debiève F; Lauwerys BR; Houssiau FA
    Arthritis Rheumatol; 2017 Jun; 69(6):1267-1271. PubMed ID: 28235250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of ovarian reserve by serum anti-Müllerian hormone in patients with systemic lupus erythematosus: a meta-analysis.
    Luo W; Mao P; Zhang L; Chen X; Yang Z
    Ann Palliat Med; 2020 Mar; 9(2):207-215. PubMed ID: 32156138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus.
    Mok CC; Chan PT; To CH
    Arthritis Rheum; 2013 Jan; 65(1):206-10. PubMed ID: 23044647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve.
    Di Mario C; Petricca L; Gigante MR; Barini A; Barini A; Varriano V; Paglionico A; Cattani P; Ferraccioli G; Tolusso B; Gremese E
    Endocrine; 2019 Feb; 63(2):369-375. PubMed ID: 30324323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of ovarian reserve with anti-Müllerian hormone in female patients with systemic lupus erythematosus].
    Chen D; Yuan S; Zhan Z; Zhan Y; Yang X; Liang L
    Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(13):977-80. PubMed ID: 24851682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Müllerian hormone in reproductive age women with systemic lupus erythematosus.
    Velarde-Ochoa Mdel C; Esquivel-Valerio JA; Vega-Morales D; Skinner-Taylor CM; Galarza-Delgado DÁ; Garza-Elizondo MA
    Reumatol Clin; 2015; 11(2):78-82. PubMed ID: 24815955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.
    Marder W; McCune WJ; Wang L; Wing JJ; Fisseha S; McConnell DS; Christman GM; Somers EC
    Gynecol Endocrinol; 2012 Aug; 28(8):624-7. PubMed ID: 22296584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of anti-Müllerian hormone levels in premenopausal patients with systemic lupus erythematosus.
    Gasparin AA; Souza L; Siebert M; Xavier RM; Chakr RM; Palominos PE; Brenol JC; Monticielo OA
    Lupus; 2016 Mar; 25(3):227-32. PubMed ID: 26223296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian reserve in adult patients with childhood-onset lupus: a possible deleterious effect of methotrexate?
    de Araujo DB; Yamakami LY; Aikawa NE; Bonfá E; Viana VS; Pasoto SG; Pereira RM; Serafin PC; Borba EF; Silva CA
    Scand J Rheumatol; 2014; 43(6):503-11. PubMed ID: 24881927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).
    Clowse ME; Copland SC; Hsieh TC; Chow SC; Hoffman GS; Merkel PA; Spiera RF; Davis JC; McCune WJ; Ytterberg SR; St Clair EW; Allen NB; Specks U; Stone JH;
    Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1777-81. PubMed ID: 22127969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide.
    Morel N; Bachelot A; Chakhtoura Z; Ghillani-Dalbin P; Amoura Z; Galicier L; Aumaitre O; Piette JC; Pourrat J; Boutin D; Sacre K; Kahn JE; Duhaut P; Farge D; Francès C; Guettrot-Imbert G; Harlé JR; Lambotte O; Le Guern V; Sène D; Trad S; Vidal E; Sarrot-Reynauld F; Gompel A; Tanguy ML; Touraine P; Lacorte JM; Costedoat-Chalumeau N;
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3785-92. PubMed ID: 23833039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study.
    Sharma SK; Jain S; Bahl P; Potturi P; Rathi M; Naidu S; Sachdeva N; Dhir V; Jain S
    Arthritis Res Ther; 2020 Aug; 22(1):189. PubMed ID: 32799907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Müllerian hormone in African-American women with systemic lupus erythematosus.
    Angley M; Spencer JB; Lim SS; Howards PP
    Lupus Sci Med; 2020 Nov; 7(1):. PubMed ID: 33132225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
    Laskari K; Zintzaras E; Tzioufas AG
    Clin Exp Rheumatol; 2010; 28(1):83-6. PubMed ID: 20346244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy.
    Aikawa NE; Sallum AM; Pereira RM; Suzuki L; Viana VS; Bonfá E; Silva CA
    Clin Exp Rheumatol; 2012; 30(3):445-9. PubMed ID: 22703605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone.
    Lawrenz B; Henes J; Henes M; Neunhoeffer E; Schmalzing M; Fehm T; Kïtter I
    Lupus; 2011 Oct; 20(11):1193-7. PubMed ID: 21768179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
    Mok CC; Lau CS; Wong RW
    Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
    Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
    Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A multicenter study on the tolerance of intravenous low-dose cyclophosphamide in systemic lupus erythematosus].
    Shao M; Guo HF; Lei LY; Zhao Q; Ding YJ; Lin J; Wu R; Yu F; Li YC; Miao HL; Zhang LY; DU Y; Jiao RY; Pang LX; Long L; Li ZG; Li R
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1112-1116. PubMed ID: 36533341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.